Protagonist Therapeutics Announces Proposed Public Offering Of $100M Shares Of Common Stock
Protagonist Therapeutics, Inc. (NASDAQ:PTGX), a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of $100,000,000 of shares of its common stock. All
